No Data
Express News | Tempest Further Strengthens Leadership Team With Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Press Release: Tempest Further Strengthens Leadership Team With Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
Scotiabank Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $13
Scotiabank analyst George Farmer maintains $Tempest Therapeutics(TPST.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 53.4%